News

Article

Australian Society of Ophthalmologists announces new board appointments

Key Takeaways

  • The ASO has appointed three new board members to enhance advocacy and efficiency within the organization.
  • Rahul Chakrabarti and Tricia Drew bring extensive ophthalmology expertise to the ASO Board, while Mark Grey is the first board member with vision impairment.
SHOW MORE

Incoming directors bring diverse expertise to help the ASO protect ophthalmic care and advocate for patients.

(Image credit: StockAdobe/Andrija)

(Image credit: StockAdobe/Andrija)

The Australian Society of Ophthalmologists (ASO) has welcomed three new members to its Board of Directors in a move to strengthen advocacy and efficiency within the organization.1

Rahul Chakrabarti, MBBS (Hons), BMedSc (Hons), MD, MSurgED (Hons), FRANZCO

Rahul Chakrabarti, MBBS (Hons), BMedSc (Hons), MD, MSurgED (Hons), FRANZCO

Rahul Chakrabarti, MBBS (Hons), BMedSc (Hons), MD, MSurgED (Hons), FRANZCO, and Tricia Drew, MBBS, BMedSci (Hons) PhD, FRANZCO, will join representative Mark Grey, from Tasmania.

ASO President Peter Sumich, MBBS (Hons), FRANZCO, highlighted the unique strengths each new director brings, emphasizing the organization’s evolving role in addressing critical health care challenges.

Chakrabarti is comprehensive general ophthalmologist at The Royal Victorian Eye and Ear Hospital in East Melbourne, Australia, and the Essendon Eye Clinic. He is director of ophthalmology training for RANZCO in Victoria, Australia.

Tricia Drew, MBBS, BMedSci (Hons) PhD, FRANZCO

Tricia Drew, MBBS, BMedSci (Hons) PhD, FRANZCO

Drew is a consultant ophthalmologist and Chair of the Eye Section, senior medical staff at The Royal Victorian Eye and Ear Hospital in East Melbourne, Australia. She is the RANZCO Younger Fellows Advisory Group State Representative for Victoria.

Mark Grey

Mark Grey

Grey’s appointment marks a milestone as the first person with vision impairment to serve on the ASO Board, according to the organization.

“We have been in a period of peacekeeping for some time but are seeing this shift as various issues across Australian health care are reaching a crisis point,” Sumich said. “With advocacy playing an essential role in the year ahead, we are pleased to announce these appointments and reaffirm that our voice — the voice of Australian ophthalmologists and their patients — is growing stronger.”

Founded in 1982, the ASO is a leader in medico-political advocacy, working to ensure excellence in ophthalmology care and equitable access to services for all Australians, according to the organization.

Reference
  1. ASO welcomes new year with incoming Board appointments. News release. Australian Society of Ophthalmologists. February 19, 2025. Accessed February 25, 2025. https://www.asoeye.org/index.cfm?module=news&pagemode=indiv&page_id=2778022

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) AGS 2025: Long-term efficacy and safety of standalone and phaco ELT with Marc Toeteberg-Harms, MD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
© 2025 MJH Life Sciences

All rights reserved.